An Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
An Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
This extended access study will assess the long-term safety and tolerability of bardoxolone methyl in qualified patients with pulmonary hypertension (PH) who previously participated in controlled clinical studies with bardoxolone methyl.
This extended access study will assess the long-term safety and tolerability of bardoxolone methyl in qualified patients with pulmonary hypertension (PH) who previously participated in controlled clinical studies with bardoxolone methyl.
Qualified patients will receive 10 mg of bardoxolone methyl once daily until the drug is available through commercial channels or until patient withdrawal, whichever is sooner. Dose de-escalation (down to 5 mg) is permitted during the study, if indicated clinically.
Inclusion Criteria:
Exclusion Criteria:
Phoenix, Arizona 85004, United States
Sacramento, California 95817, United States
Washington D.C., District of Columbia 20007, United States
Portland, Maine 04102, United States
Rochester, New York 14642, United States
Cincinnati, Ohio 45267, United States
Houston, Texas 77030, United States
Houston, Texas 77030, United States
Porto Alegre, Rio Grande do Sul 90035-074, Brazil
Mexico City, Mexico City 14000, Mexico